MicroRNA Market Overview
The MicroRNA Market is expanding rapidly as microRNAs gain importance in molecular diagnostics, oncology research, therapeutic development, and biomarker discovery. Advances in sequencing, real-time PCR, liquid biopsy, and multi-omic technologies are improving the ability to detect and characterize small non-coding RNAs, while growing investment in RNA biology is accelerating commercial applications.
According to the Market Research Future report updated August 24, 2026, the global MicroRNA Market reached USD 3.15 billion in 2025 and is projected to grow from USD 3.62 billion in 2026 to USD 13.56 billion by 2035, registering a CAGR of 15.8% during the forecast period 2026–2035. North America led the market with 39.6% of global revenue in 2025, while Asia-Pacific is the fastest-growing region at a projected CAGR of 16.1%. Real-Time PCR dominated the technology segment with a 36.3% share, while Microarray technologies are projected to grow at 14.8% CAGR. Cancer applications represented 34.0% of total demand, while Infectious Diseases are the fastest-growing application at 15.2% CAGR. Biopharmaceutical Companies generated USD 1.19 billion in 2025, while Diagnostic Centers and other clinical users are projected to grow at 15.5% CAGR. Services accounted for 45.4% of product and service revenue, while Kits and Reagents are growing at 15.1% CAGR.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
Key players driving innovation and competitiveness in the MicroRNA Market include:
Thermo Fisher Scientific
QIAGEN
Illumina
F. Hoffmann-La Roche
Bio-Rad Laboratories
Merck KGaA
Agilent Technologies
Danaher (Integrated DNA Technologies)
Takara Bio
Revvity
The MicroRNA Market is being shaped by the transition from conventional small-RNA analysis toward high-throughput, clinically oriented molecular testing. Liquid biopsy and circulating microRNA research are creating opportunities for early cancer detection and recurrence monitoring, while falling sequencing and RT-qPCR costs are making routine profiling more accessible. At the same time, pharmaceutical companies are exploring microRNA-targeting therapeutics and companion diagnostics, increasing demand for specialized assays, oligonucleotide reagents, and bioinformatics services. Standardization of sample preparation and data interpretation remains an important consideration as the industry moves from research applications toward clinical use.
The MicroRNA Market can be segmented by Technology, Application, End User, Product and Service, and Region. By technology, the market includes Real-Time Polymerase Chain Reaction, Next-Generation Sequencing, Microarray, and Immunoassay platforms. By application, it covers Cancer, Immunological Disorders, Infectious Diseases, Cardiovascular Diseases, and Other Applications. By end user, major categories include Biopharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations, and Diagnostic Centers and Others. By product and service, the market comprises Services, Kits and Reagents, and Instruments. Real-Time PCR currently leads technology adoption, while Microarray is projected to experience strong growth.
Significant opportunities are emerging from exosome-derived assays, liquid biopsy, companion diagnostics for RNA therapeutics, subscription-based bioinformatics, and laboratory expansion across emerging economies. MicroRNA panels that can support early disease detection or treatment monitoring represent an attractive commercial opportunity, while integrated extraction, sequencing, and interpretation workflows can generate recurring consumables and software revenue. Asia-Pacific and the Middle East also offer opportunities as governments expand molecular laboratory infrastructure and domestic sequencing capabilities.
Recent Developments and Market Trends:
Liquid biopsy applications are gaining momentum as circulating microRNA signatures are investigated for early cancer detection, recurrence monitoring, and patient stratification.
Real-time PCR and next-generation sequencing platforms are becoming increasingly accessible as falling costs improve the economics of small-RNA profiling.
Microarray technologies are experiencing renewed interest for high-throughput, fixed-content panels where standardized targets and lower per-sample costs are advantageous.
Pharmaceutical and biotechnology companies are increasing investment in microRNA research as RNA-targeting therapeutics and companion diagnostic programs advance.
AI-driven sequence analysis and bioinformatics platforms are gaining importance as growing volumes of microRNA data create demand for automated interpretation, target identification, and biomarker discovery.
Reasons to Buy the Report:
Understand the projected expansion of the MicroRNA Market from USD 3.15 billion in 2025 to USD 13.56 billion by 2035.
Evaluate the competitive landscape and strategic positioning of leading molecular diagnostics, sequencing, reagent, and biotechnology companies.
Identify the dominant and fastest-growing technology, application, end-user, product and service, and regional segments.
Assess the impact of liquid biopsy, RNA therapeutics, falling sequencing costs, clinical biomarker validation, and laboratory infrastructure expansion.
Gain strategic insights into companion diagnostics, exosome-derived assays, bioinformatics services, emerging-market laboratory development, and microRNA therapeutics.
Future Outlook:
The MicroRNA Market is expected to sustain strong double-digit growth through 2035 as microRNA research moves increasingly from academic discovery toward clinical diagnostics, therapeutic development, and commercial biomarker applications. Real-Time PCR will remain the dominant technology with a 36.3% share of 2025 revenue because of its established clinical laboratory base and familiarity in quantitative molecular testing, while Microarray technologies are projected to experience strong expansion at 14.8% CAGR as cost-efficient fixed-content panels gain adoption. Cancer will remain the largest application at 34.0% share, supported by liquid biopsy, early detection, and recurrence monitoring, while Infectious Diseases are expected to be the fastest-growing application at 15.2% CAGR as host-response signatures gain clinical relevance. Biopharmaceutical Companies will remain a major end-user group, generating USD 1.19 billion in 2025, while Diagnostic Centers and other clinical users are positioned for rapid growth as reimbursement and validation improve. Services will continue to dominate the product and service mix with 45.4% share because many organizations rely on outsourced sequencing and interpretation, while Kits and Reagents are projected to grow at 15.1% CAGR through recurring per-sample demand. North America will retain regional leadership with 39.6% of 2025 revenue, supported by clinical trial infrastructure, molecular diagnostic capabilities, and investment in RNA biology, while Asia-Pacific will remain the fastest-growing region at 16.1% CAGR as China, India, Japan, and other markets expand sequencing capacity and biotechnology research. Overall, liquid biopsy, RNA therapeutics, companion diagnostics, AI-powered analysis, falling molecular testing costs, and expansion of clinical laboratory infrastructure are expected to drive the MicroRNA Market to USD 13.56 billion by 2035.
➤➤Explore Our Latest Related Reports:
